The CEO's Blog — Garo H. Armen

SUBMIT A COMMENT

Presenting at the Cowen Health Care Conference

We put out an announcement this morning regarding my upcoming presentation at the Cowen conference next Tuesday, March 13, at the Boston Marriott Copley Place at 3:15 p.m.

During the presentation, I will cover how new developments underpinning the global vaccine business are transforming the industry and how Antigenics expects to participate in this significant growth through our pipeline of proprietary products as well as through our adjuvant QS-21, which is being used by major players in the vaccine marketplace:

• QS-21, our potent adjuvant, is currently used as a key component of a new generation of vaccines by GlaxoSmithKline, Élan, Wyeth and others to enable many of their vaccines to be effective. GSK, the world leader in vaccines, has the most extensive pipeline in the business and uses QS-21 in most of its advanced vaccine formulations, as declared by GSK's head of research at a recent FDA cancer vaccine workshop.
• Oncophage, our investigational therapeutic cancer vaccine, has completed a Phase 3 clinical trial that indicated a potentially significant benefit in a large subset of renal cell carcinoma patients. We are exploring possible commercialization of Oncophage outside the US as a first step while we keep a close eye on potential regulatory reform in the US -- specifically regarding cancer vaccines (also discussed as the key topic at the same FDA workshop).
• AG-707, our therapeutic vaccine candidate for genital herpes, is in Phase 1 development.

I will also cover our investigational chemotherapeutic product Aroplatin, which is finishing Phase 1 trials.

Our homepage also lists reports from brokerage houses and consulting firms outlining how a new generation of preventative and therapeutic cancer vaccines are creating a new and vibrant vaccine business. Many of our collaborators are the leaders in this emerging field of new generation of vaccines and we are excited about the opportunities this presents for Antigenics through multiple products and platforms.

I look forward to seeing those of you attending the conference or having you listen to the webcast.

This communication contains forward-looking statements, including statements regarding the opportunities in the vaccine marketplace and the benefits to Antigenics; the potential market for, and the growth in development of products containing QS-21 by the company’s collaborative partners and licensees; the current and future development and commercialization activities for Oncophage; and the company’s Phase 1 clinical programs involving Aroplatin and AG-707. These risks and uncertainties include, among others, unfavorable data resulting from the analysis of the Oncophage Phase 3 Part 1 kidney cancer trial data; retention of key employees; clinical trial enrollment; decisions by collaborative partners and licensees; decisions by regulatory agencies; timing and results of clinical and preclinical studies; timely and successful development of QS-21 manufacturing capabilities; and the factors described under Factors That May Impact Future Results in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics’ Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2006. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this call. These statements speak only as of the date of the communication, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics’ business and securities, investors should give careful consideration to these risks and uncertainties.

Comments

Posted by: Bryan (03/20/2007)
Comment: Garo, Congradulations on the recent insider buys. Having the CEO put money into AGEN makes me as a shareholder feel better about my investment. I also found the link to the ABC interview with Dr Andrew Parsa and the Reuters article concerning QS-21, most informative. Thanks, Bryan

Posted by: Tim (03/29/2007)
Comment: I have been a holder of Antigenics stock for a number of years and I still have considerable confidence in the management and the company’s long-term future. It is good to see the CEO purchasing more stock, something which I certainly aim to do too. It is good to be part of a company that is as transparent as this and communicates so well. And I commend you on this blog. Keep up the good work!

SUBMIT A COMMENT